Italian biotech Thena Biotech S.r.l. has initiated a first-in-human Phase I trial of THE-0504, an engineered human ferritin nanoparticle loaded with the topoisomerase I inhibitor Genz-644282, in patients with heavily pretreated solid tumors. The trial is notable for applying a conditionally activatable protein nanocage — rather than a conventional antibody-drug conjugate scaffold — to targeted cytotoxic delivery, an approach that remains largely unvalidated in humans despite substantial preclinical interest.
The NANOFER-THE-0504 study (NCT07646106), conducted at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, is enrolling up to 30 adults with measurable or locally advanced unresectable disease across five tumor types: small cell lung cancer, colorectal carcinoma, pancreatic adenocarcinoma, gastric cancer, and triple-negative breast cancer. All participants must have exhausted EMA-approved treatment options, positioning this as a salvage-setting study. THE-0504 is administered intravenously on days 1 and 8 of a 21-day cycle, with dose escalation following a 3+3 design and intra-patient escalation permitted. Primary endpoints are maximum tolerated dose and recommended Phase II dose; secondary endpoints include objective response rate and progression-free survival per RECIST 1.1, assessed over up to 36 months. Primary completion is expected by May 2027.
THE-0504 exploits the natural affinity of human heavy-chain ferritin for CD71 (transferrin receptor 1, TfR1), which is overexpressed across multiple solid tumor lineages relative to normal tissue. The ferritin nanocage homes to CD71-positive tumor cells; a tumor protease-sensitive element within the construct then triggers intracellular release of Genz-644282, a non-camptothecin TOP1 inhibitor originally developed by Genzyme. The conditional activation design is intended to limit systemic exposure to the payload — a meaningful consideration given that Genz-644282 itself did not advance as a free drug, presumably due to tolerability constraints. The platform and patent (EP3186192B1) originate from researchers at the National Research Council of Italy's Institute of Molecular Biology and Pathology, with inventors Pierpaolo Ceci and Elisabetta Falvo named on the patent held by Thena Biotech; Ceci was formally seconded to the company as scientific lead, according to published preclinical work.
The most relevant clinical precedent for CD71-targeted cytotoxic therapy is CytomX Therapeutics' CX-2029, a protease-activated anti-CD71 ADC that advanced into Phase II testing before being discontinued following AbbVie's termination of the partnership in 2023. The program highlighted both the appeal and the challenge of targeting transferrin receptor 1, which is highly expressed in many cancers but also present on normal proliferating tissues.